Pharmaceutical medicine · 2026
Changes in Saccadic Hypometria over Time to Monitor Parkinson's Disease Progression.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ben-Ami Edmund, Raveh Eitan, Harpaz Eran, Riklin Igal, Band Tali, Gurevich Tanya, Alcalay Roy N, Mir Pablo, Tosin Michelle H S, Goetz Christopher G, Rascol Olivier
Аннотация
BACKGROUND: Eye movement biomarkers are emerging as promising tools for monitoring neurodegenerative diseases in clinical trials. Saccadic hypometria, the reduced saccade amplitude leading to undershooting visual targets, is a recognized feature of Parkinson's disease (PD), correlated with motor symptoms severity in cross-sectional studies. However, its use as a biomarker to monitor disease progression has not been studied.
OBJECTIVES: The aim was to assess the sensitivity and reproducibility of saccadic hypometria as a biomarker of PD progression.
METHODS: The amplitude of saccadic hypometria (ASH) was measured in two cohorts: a single-center cohort (SCC) (30 PD patients, 50 healthy controls) followed by a multicenter cohort (MCC) (250 PD patients, 91 healthy controls across 4 sites). Assessments occurred every 3 months over 9 months using a software-based platform (NeuraLight). Motor symptoms were assessed with the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III. ASH and MDS-UPDRS changes were analyzed using individual slopes of change and compared between groups.
RESULTS: ASH significantly declined over time in PD patients compared to controls in both cohorts (SCC: - 1.96 ± 4.14% vs. 0.33 ± 1.75%, P < 0.01; MCC: - 1.05 ± 3.09% vs. 0.54 ± 1.85%, P < 0.001), and these changes were consistent across MCC sites. MDS-UPDRS III scores remained unchanged over the same period in the SCC, and changes were highly variable across MCC sites, resulting in a non-statistically significant change over time.
CONCLUSION: ASH progressively worsened in PD patients over 9 months, even when standard clinical scales showed no significant change. These findings support ASH as a sensitive, objective, and quantitative biomarker for monitoring PD progression.
OBJECTIVES: The aim was to assess the sensitivity and reproducibility of saccadic hypometria as a biomarker of PD progression.
METHODS: The amplitude of saccadic hypometria (ASH) was measured in two cohorts: a single-center cohort (SCC) (30 PD patients, 50 healthy controls) followed by a multicenter cohort (MCC) (250 PD patients, 91 healthy controls across 4 sites). Assessments occurred every 3 months over 9 months using a software-based platform (NeuraLight). Motor symptoms were assessed with the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III. ASH and MDS-UPDRS changes were analyzed using individual slopes of change and compared between groups.
RESULTS: ASH significantly declined over time in PD patients compared to controls in both cohorts (SCC: - 1.96 ± 4.14% vs. 0.33 ± 1.75%, P < 0.01; MCC: - 1.05 ± 3.09% vs. 0.54 ± 1.85%, P < 0.001), and these changes were consistent across MCC sites. MDS-UPDRS III scores remained unchanged over the same period in the SCC, and changes were highly variable across MCC sites, resulting in a non-statistically significant change over time.
CONCLUSION: ASH progressively worsened in PD patients over 9 months, even when standard clinical scales showed no significant change. These findings support ASH as a sensitive, objective, and quantitative biomarker for monitoring PD progression.